common.study.topics.clinical

Treatment of Ovarian Cancer Patients

common.study.values.description

A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy

This is a Phase 3, randomized, multinational, double-blind, dual placebo-controlled, 4-arm study evaluating rucaparib and nivolumab as maintenance treatment following response to front-line treatment in newly diagnosed ovarian cancer patients. Response to treatment will be analyzed based on homologous recombination (HR) status of tumor samples.

common.study.values.location

participant.ui.study.affiliations-map.online-study.header-virtual

participant.ui.study.affiliations-map.online-study.text

participant.ui.study.affiliations-map.legend.locations participant.ui.study.affiliations-map.legend.selected

common.study.values.methods

Pharmaceutical medication involved common.study.methods.has-drugs-yes
Recruiting patients only common.study.methods.is-healthy-yes

Drug - Rucaparib

Oral rucaparib will be administered twice daily

Drug - Nivolumab

IV nivolumab will be administered once every 4 weeks

Drug - Placebo Oral Tablet

Placebo tablets will be administered twice daily

Drug - Placebo IV Infusion

IV placebo will be administered once every 4 weeks

participant.views.study.view.additional

participant.views.study.view.scientific-title

ATHENA (A Multicenter, Randomized, Double-Blind, Placebo- Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy)

common.study.values.clinical-trial-id

NCT03522246

participant.views.study.view.id

RdGGKd